

sleep. "The fact that a substantial portion of American children achieve such small amounts of sleep should be of concern in light of findings from prior studies suggesting associations between poor sleep hygiene and decreased cognitive and social functioning," they wrote.

The investigators also noted that "the shift towards later weekday bedtimes might begin earlier than some researchers have suspected," occurring in preadolescence, as early as age 8 or 9 years. "There is clear evidence for the appropriateness of later bedtimes for adolescents, as these changes ... may be biologically driven. ... For younger children, however, the change

to later bedtimes may be driven more by social factors rather than changes in biology," they suggested.

The study also found that lost sleep shows up on the scales 5 years later—with later bedtimes for younger children (aged 3-7.9 years) having the most impact on subsequent body mass index (BMI), while later wake times were more important for older children (aged 8-12.9 years) and subsequent BMI. "Even 1 additional

hour of sleep may have a significant and meaningful effect on BMI and overweight status," they wrote, noting that at baseline, 1 extra hour of sleep above average lowered a child's risk of being overweight 5 years later—from 36% to 30%, even after controlling for baseline BMI, family socioeconomic, and race. The study found no evidence that gender or physical activity influenced the effect of sleep on BMI.

The mediating pathway between inadequate sleep and weight gain may be the disruption of hormones that regulate appetite and metabolism.

The mediating pathway between inadequate sleep and weight gain may be the disruption of hormones that regulate appetite and metabolism, suggested the authors, "with insufficient sleep hours causing reduced levels of leptin and increased levels of ghrelin, a hormonal profile associated with increased hunger and appetite for carbohydrate-rich foods."

The investigators suggested that a combination of strategies geared toward earlier bedtimes and later wake times depending on a child's age "might well improve multiple aspects of children's health, emotional well-being, and academic performance." ■

Neonatal Weight Gain Linked to Adult Obesity

CHICAGO — Rapid weight gain in the first week of life in formula-fed infants is associated with increased risk of obesity 2-3 decades later, Dr. Nicolas Stettler said at the annual scientific sessions of the American Heart Association.

"The neonatal period may be a sensitive period for the programming of energy balance regulation," said Dr. Stettler of Children's Hospital of Philadelphia.

He presented an observational study conducted over several decades. It involved 653 formula-fed white infants born in the Iowa City area. At age 20-32 years, 32% of them were overweight or obese.

Using a relatively recent statistical analysis method called life-course modeling, Dr. Stettler and coworkers were able to identify the first 8 days of infancy as a critical period of weight gain associated with adult obesity.

The median weight gain during the first 8 days of life was about 200 g. After the researchers adjusted for birth weight, maternal overweight, and other potential confounders, early weight gain remained an independent predictor of adult overweight; for each 100-g increase in weight, the risk of adult overweight or obesity rose by about 28%. This was true even among babies with a low birth weight and rapid catch-up.

Thus, an individual who gained 200 g in the first week of life had a 32% chance of becoming an overweight adult, one who gained 300 g had a 41% risk, and a 400-g weight gain was associated with a 55% risk, Dr. Stettler said.

The importance of this large study of early weight gain isn't so much that it permits identification of individuals at risk for adult obesity; after all, obesity is now so common. Rather, the study is important mainly for its public health and research implications. The results, Dr. Stettler said, may eventually open the door to novel brief interventions in infancy to prevent later obesity. For example, the findings are consistent with animal studies that suggest overfeeding in the first few days of life may result in neurologic or endocrinologic imprinting leading to later obesity.

The first week of life is the first time an individual has to regulate energy intake, he noted. During the fetal period, nutrients are provided passively.

—Bruce Jancin

Know the risk

Younger adolescents are also at increased risk for meningococcal disease¹

Recommend vaccination to reduce the risk

- Menactra vaccine is highly immunogenic following a **single 0.5mL intramuscular injection**^{1,2}
- Produces a strong booster response in adolescents previously vaccinated against meningococcal disease²



CPT** Code: 90734

Menactra®
Meningococcal
(Groups A,C,Y and W-135)
Polysaccharide Diphtheria
Toxoid Conjugate Vaccine

To order, log onto
www.vaccineshoppe.com or
call 1-800-VACCINE (1-800-822-2463).

**Protect them as if they were your own—
Talk with patients today about
meningococcal disease and the
benefits of vaccination**

Safety Information

Menactra vaccine is indicated for active immunization against invasive meningococcal disease caused by *N meningitidis* serogroups A, C, Y, and W-135 in persons 11 through 55 years of age. Menactra vaccine will not stimulate protection against infection caused by *N meningitidis* other than serogroups A, C, Y, and W-135. As with any vaccine, vaccination with Menactra vaccine may not protect 100% of individuals.

There are risks associated with all vaccines. The most common adverse reactions to Menactra vaccine include pain, redness, and induration at the site of injection, headache, fatigue, and malaise. Menactra vaccine is contraindicated in persons with known hypersensitivity to any component of the vaccine or to latex, which is used in the vial stopper. Guillain-Barré Syndrome (GBS) has been reported in temporal relationship following administration of Menactra vaccine. Persons previously diagnosed with GBS should not receive Menactra vaccine. Because any intramuscular injection can cause injection site hematoma, Menactra vaccine should not be given to persons with any bleeding disorder, such as hemophilia or thrombocytopenia, or to persons on anticoagulant therapy unless the potential benefits clearly outweigh the risk of administration. If the decision is made to administer Menactra vaccine to such persons, it should be given with caution, with steps taken to avoid the risk of hematoma formation following injection. Before administering Menactra vaccine, please see brief summary of full Prescribing Information on adjacent page.

References: 1. Sanofi Pasteur Inc. Data on file (Study MTA02). September 2003. MKT9271-1. 2. Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. *Arch Pediatr Adolesc Med.* 2005;159:907-913.

*CPT is a registered trademark of the American Medical Association.

Menactra vaccine is manufactured and distributed by Sanofi Pasteur Inc.

sanofi pasteur
Discovery Drive, Swiftwater, Pennsylvania 18370
www.sanofipasteur.us

MKT12617-2 ©2007 Sanofi Pasteur Inc. 1/07 Printed in USA

sanofi pasteur
The vaccines business of sanofi-aventis Group